Comparison
While Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While Setmelanotide works as a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
Setmelanotide is amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. Setmelanotide is made up of a sequence of sequence data not available in the current dataset. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
Setmelanotide
POMC
Tirzepatide
Not assigned in the current dataset.